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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
1. To compare individual active drugs (antidepressants, benzodiazepines and azapirones) and placebo in terms of efficacy and
acceptability in the acute treatment of panic disorder, with or without agoraphobia.
2. To rank treatments for panic disorder (antidepressants, benzodiazepines, azapirones and placebo) according to their effectiveness
and acceptability.
B A C K G R O U N D
Description of the condition
A panic attack is a discrete period of fear or anxiety that has a
rapid onset, reaches a peak within 10minutes and in which at least
4 of 13 characteristic symptoms are experienced. Many of these
symptoms involve bodily systems, such as racing heart, chest pain,
sweating, shaking, dizziness, flushing, churning stomach, faintness
and breathlessness. Further recognised panic attack symptoms in-
volve fearful cognitions, such as the fear of collapse, going mad or
dying, and derealisation (APA 1994).
Panic disorder first entered diagnostic classification systems in
1980 with the publication of DSM-III, following observations
that patients with panic attacks responded to treatment with the
tricyclic antidepressant (TCA) imipramine (Klein 1964). To di-
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agnose panic disorder, further conditions must be met relating to
the frequency of attacks, the need for some to come on ‘out of
the blue’ rather than in a predictable, externally-triggered situa-
tion, and exclusions where attacks are attributable solely to med-
ical causes or panic-inducing substances, notably caffeine. DSM-
IV requires additionally that at least one attack has been followed
by either: a) persistent concern about having additional attacks,
b) worry about the implications of the attack or its consequences,
or c) a significant change in behaviour related to the attacks (APA
1994). The core features of panic attacks remained unchanged in
the DSM-5 (APA 2013), but in DSM-5 panic disorder and agora-
phobia are no longer linked and are now coded in two diagnoses
(APA 2013a).
Panic disorder is common in the general population with a lifetime
prevalence of 1% to 4% (Eaton 1994; Bijl 1998; Kessler 2012). In
primary care settings, panic syndromes have been reported to have
a prevalence of around 10% (King 2008). Its aetiology is not fully
understood and is probably heterogeneous. Biological theories in-
corporate the faulty triggering of an inbuilt anxiety response, pos-
sibly a suffocation alarm. Evidence for this comes from biological
challenge tests (lactate and carbon dioxide trigger panic in those
with the disorder) and from animal experiments and neuroimag-
ing studies in humans that show activation of fear circuits, such
as that involving the periaqueductal grey matter (Gorman 2000).
Agoraphobia is anxiety about being in places or situations from
which escape might be difficult or embarrassing, or in which help
may not be available in the event of having a panic attack (APA
2013). Agoraphobia can occur with panic disorder (APA 2013).
About one quarter of people suffering from panic disorder also
have agoraphobia (Kessler 2006). The presence of agoraphobia
is associated with increased severity and worse outcome (Kessler
2006). There are several risk factors that predict the develop-
ment of agoraphobia in people suffering from panic disorder: fe-
male gender, more severe dizziness during panic attacks, cognitive
factors, dependent personality traits and social anxiety disorder
(Starcevic 2009).
Panic disorder, with or without agoraphobia, is highly comorbid
with other psychiatric disorders, such as drug dependence, major
depression, bipolar I disorder, social phobia, specific phobia, and
generalised anxiety disorder (Grant 2006). It is estimated that
generalised anxiety disorder co-occurs in 68%of people with panic
disorder, whilst major depression has a prevalence of 24% to 88%
among people with panic disorder (Starcevic 2009).
Description of the intervention
The treatment of panic disorder includes psychological and phar-
macological interventions, often used in combination (Furukawa
2007; Watanabe 2009). Historically, pharmacological interven-
tions for panic disorder have been based on the use of mono-
amino oxidase inhibitors (MAOIs) and tricyclic antidepressants
(TCAs) (Bruce 2003). However, MAOIs and TCAs are burdened
by severe adverse effects, such as dietary restrictions (to avoid
hypertensive crisis) for MAOIs, and anticholinergic, arrhythmo-
genic and overall poor tolerability for TCAs (Wade 1999). Ben-
zodiazepines (BDZs), particularly high potency ones, have been
used as a safer alternative in panic disorder (Stein 2010), although
the long-term outcome may be less good (NICE 2011). Recent
international guidelines (BAP 2005; APA 2009; NICE 2011)
consider antidepressants, mainly selective serotonin reuptake in-
hibitors (SSRIs), as the first-line treatment for panic disorder, due
to their more favourable adverse effect profile over MAOIs and
TCAs. A meta-analysis comparing SSRIs and TCAs in panic dis-
order (Bakker 2002) showed that SSRIs are as effective as TCAs,
and are better tolerated, although other studies showed a possi-
ble overestimation of the efficacy of SSRIs over older antidepres-
sants in panic disorder (Anderson 2000; Otto 2001). BDZs have
higher incidence of dependence and withdrawal reaction when
compared to antidepressants (Wade 1999) and may not be effec-
tive in treating panic disorder that is comorbid with depression
(Ballenger 1998). In spite of these caveats, it appears that BDZs
continue to be widely prescribed for the treatment of panic dis-
order (Bruce 2003). More recently, new research in psychophar-
macology has focused on azapirones (Imai 2014), a class of drugs
used as anxiolytics, because they seem to be associated with less
drowsiness, psychomotor impairment, alcohol potentiation and
potential for addiction or abuse than BDZs (Napoliello 1991). Ex-
amples include alnespirone, binospirone, buspirone, enilospirone,
eptapirone, gepirone, ipsapirone, revospirone, tandospirone and
zalospirone, all of which are serotonin 1A (5-HT1A) receptor par-
tial agonists. Other properties include 5-HT2A and α1- and α2-
adrenergic receptor antagonism, which differ between individual
drugs (Kishi 2013).
How the intervention might work
Themain classes with evidence of efficacy in panic disorder are an-
tidepressant drugs that augment the function of the monoamines
serotonin and/or noradrenaline. Considering the serotonergic an-
tidepressants (SSRIs such as fluoxetine, paroxetine, sertraline and
citalopram) - these drugs promote the transmission of the neuro-
transmitter serotonin across brain synapses; most notably in the
dorsal raphe nucleus (Briley 1993). They prevent reuptake of sero-
tonin into nerve terminals by inhibiting serotonin transporters,
thus allowing more to be available for neurotransmission. In panic
disorder, imaging studies have revealed reduced expression of the
5H1A receptor (Nash 2008) which has an inhibitory function, so
the increased serotonin throughput may in part serve to overcome
this deficit of inhibition. Noradrenergic antidepressants can sim-
ilarly increase transmission of the catecholamine noradrenaline.
Some antidepressants such as the serotonin-norepinephrine re-
uptake inhibitor (SNRI) drugs (e.g. venlafaxine, duloxetine) and
TCAs can enhance both serotonin and noradrenaline transmis-
sion by inhibiting both transporters. BDZs moderate the gamma-
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Aminobutyric acid (GABA) neurotransmitter system, which is the
brain’s main inhibitory neurotransmitter. They act as agonists at
the GABA-A BDZ receptor. This complex contains a chloride
channel which can be opened by agonists which ultimately pro-
duce anxiolysis and sedation. The BDZ binding site communi-
cates only indirectly with the channel, meaning that BDZs are
safer than their predecessors, the barbiturates. It is known through
imaging studies that the inhibitory GABA system is deficient in
panic disorder (Malizia 1998; Cameron 2007) and thus BDZs’
ability to act as agonists at the GABA-A BDZ receptor can coun-
teract this. It is likely that both monoamine-based systems and
GABA-based systems converge, allowing both antidepressants and
BDZs to have efficacy in panic disorder despite their differing ac-
tions on neurotransmitter systems. One possibility is via seroton-
ergic neurons that modulate GABA input to the periaqueductal
grey matter.
The exact mechanism of action of azapirones in anxiety disorders
has not been established, but they are known to be partial agonists
at the serotonin 5-HT1A receptor and potentially as antagonist at
dopamine D2 and D3 receptors (Tauscher 2001; Diaz 2011). Al-
though the dopaminergic theory of azapirone action remains un-
proven, evidence in humans is emerging to confirm that standard
therapeutic doses of azapirones such as buspirone can achieve sig-
nificant D3 receptor occupancy (Payer 2013). Finally, azapirone
inhibition of α2-adrenoceptors on serotonergic neurons may also
play a role in the anxiolytic effects of buspirone. As these recep-
tors moderate serotonin release, azapirone may be instrumental in
increasing overall serotonin availability through this mechanism.
Why it is important to do this review
Antidepressants and BDZs are widely used in clinical practice to
treat panic disorder; however, no comprehensive, systematic stud-
ies on thematter have been conducted recently. To our knowledge,
the last meta-analysis specifically focused on benzodiazepines for
panic disorder was published in 1991 (Wilkinson 1991) and the
last meta-analysis focusing on antidepressants for this condition
was published more than 10 years ago (Bakker 2002). The role of
azapirones in panic disorder is still unclear, with only few stud-
ies published on the topic (Sheehan 1990; Imai 2014). Standard
pair-wise meta-analyses of psychopharmacological interventions
in panic disorder are under way within Cochrane (Guaiana 2013a;
Guaiana 2013b; Imai 2014; Bighelli 2016). Other reviews have
been published on combined psychotherapy and pharmacother-
apy in panic disorder (Furukawa 2007; Watanabe 2009). How-
ever, given the complexity of the condition and the lack of recent
data from systematic reviews on the matter, it is very important
to carry out a comprehensive and comparative evaluation of all
available treatment options within the framework of a network
meta-analysis (NMA). Assessing which treatments, if any, are the
most effective and safe, this NMAwill help patients, mental health
professionals and policy makers identify the best pharmacological
treatments for panic disorder, in order to improve clinical practice
and patient care.
O B J E C T I V E S
1. To compare individual active drugs (antidepressants,
benzodiazepines and azapirones) and placebo in terms of efficacy
and acceptability in the acute treatment of panic disorder, with
or without agoraphobia.
2. To rank treatments for panic disorder (antidepressants,
benzodiazepines, azapirones and placebo) according to their
effectiveness and acceptability.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will only include double-blind randomised controlled trials
(RCTs) comparing against each other, one of the following drugs
(see the list below) or placebo, in the acute treatment of panic
disorder. Trials inwhich drugs are used as an augmentation strategy
to any other psychotropic drugs will be excluded. For trials which
have a cross-over design, we will only consider results from the first
randomisation period. Cluster-randomised trials will be included
only if intracluster correlation coefficients are reported.
We will exclude:
• relapse prevention trials;
• studies in patients with a diagnosis of panic disorder where
the effects of treatments are measured after panic attacks have
been induced (for example with CO2 inhalations or lactate
infusions);
• studies administering psychosocial therapies targeted at
panic disorder concurrently;
• studies comparing psychosocial interventions; and
• quasi-randomised trials.
Types of participants
The fundamental assumption underpinning a networkmeta-anal-
ysis is that of consistency/transitivity (Caldwell 2005; Cipriani
2013). We assume that any patient who meets the inclusion crite-
ria below is, in principle, equally likely to have been randomised
to any of the eligible interventions examined in this review, i.e.
they are ’jointly randomisable’ (Salanti 2012).
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Participant characteristics
Patients aged 18 or older, of either sex, with a primary diagnosis
of panic disorder, with or without agoraphobia.
Diagnosis
Diagnosis will be according to any of the following criteria: DSM-
III-R, DSM-IV or ICD-10. We will not adopt studies using op-
erationalised criteria before DSM-III-R because their conceptual-
isation of panic disorder is substantively different.
Comorbidities
When the study eligibility focuses on agoraphobia rather than
panic disorder, and is operationally diagnosed according to the
above-named criteria, and when it can be safely assumed that at
least some of the patients are suffering from panic disorder as de-
fined by the above criteria, such a study can still be included. Con-
sidering that over 95% of patients with agoraphobia seen clinically
suffer from panic disorder as well (Goisman 1995), the effect of
their inclusion will be examined in a subgroup analysis. Trials in
which all participants have a concurrent primary diagnosis of Axis
I or II disorders other than panic disorder or agoraphobia will be
excluded if the focus is not the treatment of panic disorder. We
will exclude trials in which participants have a serious concomitant
medical illness.
Setting
Inpatient, outpatient and primary care.
Subset data
Trials that provide data on a relevant subset of their participants
will not be included.
Types of interventions
We will include only studies where medications were used at ther-
apeutic dosage. We define therapeutic doses as doses that are in-
dicated for panic disorder by any of the North American, Euro-
pean or Japanese regulatory agencies. Where such are not avail-
able, we will follow the same dose ranges as for major depression
(for antidepressants) and generalised anxiety disorder (for benzo-
diazepines).
Antidepressants
• TCAs and heterocyclics antidepressants: clomipramine,
desipramine, dosulepin/dothiepin, doxepin, impiramine,
lofepramine, maprotiline, nortriptyline.
• Selective serotonin reuptake inhibitors: citalopram,
escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline.
• Monoamine-oxidase inhibitors: moclobemide, phenelzine,
tranylcypromine.
• Serotonin-noradrenaline reuptake inhibitors:
desvenlafaxine, duloxetine, milnacipran, venlafaxine.
• Noradrenergic and specific serotonergic antidepressants:
mirtazapine.
• Noradrenergic and dopaminergic reuptake inhibitors:
bupropion.
• Noradrenergic reuptake inhibitors: reboxetine.
• Others: agomelatine, trazodone, nefazodone, mianserin,
maprotiline, vortioxetine and non-conventional herbal products
(e.g. Hypericum)
Benzodiazepines (BDZs)
Alprazolam, bretazenil, bromazepam, chlordiazepoxide, cino-
lazepam, clonazepam, cloxazolam, clorazepate, deloramzeapam,
diazepam, estazolam, etizolam, fludiazepam, flunitrazepam, flu-
razepam, flutoprazepam, halazepam, ketazolam, loprazolam, lo-
razepam, lormatezepam, medazepam, nimatazepam, nitrazepam,
nodazepam, oxazepam, phenazepam, pinazepam, prazepam, pre-
mazepam, quazepam, temazepam, tetrazepam, triazolam and any
other drug belonging to the BDZ class.
Azapirones
Alnespirone, binospirone, buspirone, enilospirone, eptapirone,
gepirone, ipsapirone, revospirone, tandospirone and zalospirone.
Placebo
Placebo can be active (i.e. mimicking side effects) or inactive (com-
pletely inert). We will include studies using active and inactive
placebo. This could be a potential source of intransitivity.
If a study has two or more arms at different doses of the same
medication within the therapeutic range, we will combine groups
to create a single pair-wise comparison, as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (chapter
16.5.4) (Higgins 2011).
Types of outcome measures
Studies that meet the above inclusion criteria will be included
regardless of whether they report on the following outcomes.
Primary outcomes
1. Response to treatment (i.e. substantial improvement from base-
line as defined by the original investigators). We will consider as re-
sponse the following definitions: “much or very much improved”
according to the Clinical Global Impression Change Scale; more
than 40% reduction in the Panic Disorder Severity Scale score; or
4Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
more than 50% reduction in the Fear Questionnaire Agorapho-
bia Subscale. When multiple measures are used, preference will be
given to the most global measure.
2. Total number of dropouts due to any reason (as a proxymeasure
of treatment acceptability).
Secondary outcomes
3. Remission (i.e. satisfactory end-state as defined by global judg-
ment of the original investigators). Examples would be “panic free”
and “no or minimal symptoms” according to the Clinical Global
Impression Severity Scale.Whenmultiple measures are used, pref-
erence will be given to the most global measure.
4. Panic symptom scales and global judgment on a continuous
scale. Examples include Panic Disorder Severity Scale total score
(0 to 28), Clinical Global Impression Severity Scale (1 to 7), and
Clinical Global Impression Change Scale (1 to 7).
5. Frequency of panic attacks (as recorded, for example, by a panic
diary).
6. Agoraphobia (as measured, for example, by the Fear Question-
naire, Mobility Inventory, or behavioural avoidance test).
Whenmore than one scale is available in the paper, preference will
be given in the following order:
• PDSS > Panic and Agoraphobia Scale (PAS) > ASI-R > ASI
> ACQ > BSQ > other scales specific for panic disorder;
• CGI-S > CGI-I > GAS > GAF > other global scales;
• FQ-ag > FQ-global > Mobile Inventory for Agoraphobia-
Avoidance-Alone (MI-AAL) > MI-Avoidance-Accompanied
(MI-AAC) > other scales specific for agoraphobia only; and
• Panic frequency > panic severity > other scales specific for
panic attacks only.
Once the scale has been chosen, if both self- and observer-rated
assessments are available, preference will be given to the latter. The
actual measure entered into the meta-analysis is indicated at the
top of the listings in the table ’Characteristics of included studies’.
Timing of outcome assessment
All outcomes are short-term, which we define as acute phase treat-
ment which normally would last two to six months. When studies
report more response rates at different time points within two to
six months, the time point closest to three months (i.e. 12 weeks)
will be given preference.
Hierarchy of outcome measures
When several possible outcome measures are reported for the same
outcome, we will use the primary outcome according to the orig-
inal study.
Search methods for identification of studies
Trials which include at least two of the interventions are eligible for
inclusion in the review. We will search for all possible comparisons
formed by the interventions of interest, as defined above.
The Cochrane Common Mental Disorders
Specialised Register (CCDANCTR)
The Cochrane Common Mental Disorders Group (CCMD)
maintains two clinical trials registers at its editorial base in Bristol,
UK: a references register and a studies-based register. The CC-
DANCTR-References Register contains over 37,500 reports of
RCTs in depression, anxiety and neurosis. Approximately 60%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-
Psi coding manual, using a controlled vocabulary. The CCDAN
Information Specialist is able to provide further details. Reports of
trials for inclusion in theGroup’s registers are collated from routine
(weekly), generic searches of MEDLINE (1950-), Embase (1974-
) and PsycINFO (1967-); quarterly searches of the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) and review-specific
searches of additional databases. Reports of trials are also sourced
from international trials registers via the World Health Organiza-
tion’s trials portal (the International Clinical Trials Registry Plat-
form (ICTRP)), pharmaceutical companies, the handsearching of
key journals, conference proceedings and other (non-Cochrane)
systematic reviews and meta-analyses.
Details of CCMD generic search strategies (CCDAN’s generic
search strategies) (used to identify RCTs) can be found on the
Group’s website.
Electronic searches
1. Cochrane Specialised Register
The CCDANCTR-Studies Register will be searched on condition
alone.
Condition = panic
Records will be manually screened for drug therapy trials.
The CCDANCTR-References Register will be searched using a
more sensitive set of free-text terms to identify additional un-
tagged/uncoded reports of RCTs (Appendix 1).
A further search of theCCDANCTRwill be conducted to identify
drug therapy trials for ‘AnxietyDisordersNotOtherwise Specified’
(ADNOS), which may include a subset of participants with panic
disorder.
No restrictions on date, language or publication status will be
applied to the searches.
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2. Biomedical database searches
With the relocation of the Cochrane Common Mental Disorders
Group to the University of York in 2016, the CCMDCTR is
currently out-of-date, so additional searches will also need to be
conducted on the following databases:
1. Cochrane Library (http://www.cochranelibrary.com/)
(latest issue);
2. Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid OLDMEDLINE(R) (2014 to date);
3. Ovid Embase (2014 to date); and
4. Ovid PsycINFO (2014 to date).
Full search strategies are displayed in Appendix 2.
3. International trial registries
International trial registries will be searched via the World Health
Organization’s trials portal (ICTRP) and ClinicalTrials.gov to
identify unpublished or ongoing studies.
Searching other resources
Two review authors will check independently the reference lists of
all included studies, non-Cochrane systematic reviews and major
textbooks of affective disorders (written in English), for published
reports and citations of unpublished research. A citation search
will also be conducted via the Web of Science (included studies
only) to identify additional works. We will also contact experts in
the field.
Data collection and analysis
Selection of studies
At least two review authors will independently screen titles and
abstracts for inclusion of all the studies we identify as a result of the
search and code them as ’retrieve’ (eligible or potentially eligible/
unclear) or ’do not retrieve’. We will retrieve the full-text study
reports/publications and two review authors will independently
screen them and identify studies for inclusion, and identify and
record reasons for exclusion of the ineligible studies. The two
review authors will resolve any disagreement through discussion
or, if required, theywill consult a thirdmember of the review team.
We will identify and exclude duplicate records and we will collate
multiple reports that relate to the same study so that each study
rather than each report is the unit of interest in the review. We
will record the selection process in sufficient detail to complete a
PRISMA flow diagram and ’Characteristics of excluded studies’
table (Moher 2009).
Data extraction and management
We will use a data collection form to extract study characteristics
and outcome data, which has been piloted on at least one study in
the review. Two authors from the review team will extract study
characteristics and outcome data from included studies.
From each included study we will extract data on the following
study, intervention and population characteristics that may act as
effect modifiers.
1. Methods: study design, randomisation (individual or
cluster), total duration of study, number of study centres and
location, study setting, withdrawals, and date of study.
2. Participants: number, setting, diagnostic criteria, presence
or absence of medical and psychiatric comorbidities, presence or
absence of elderly participants, percentage of patients with
agoraphobia, percentage of patients with baseline depression,
inclusion criteria, and exclusion criteria.
3. Interventions: medication dose, medication dose range, use
of rescue medication.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported. Where possible we will
extract data at the arm level, not summary effects.
5. Notes: sponsorship/funding for trial, and notable conflicts
of interest of trial authors.
We plan to compile a table of important trial and patient charac-
teristics and visually inspect the similarity of factors we consider
likely to modify treatment effect.
We will note in the ’Characteristics of included studies’ table if
outcome data were not reported in a usable way. We will resolve
disagreements by consensus or by involving a third person. One
review author will transfer data into the ReviewManager (RevMan
2014) file. We will double-check that data are entered correctly
by comparing the data presented in the systematic review with
the study reports. A second review author will spot-check study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
To assess the quality (internal validity) of trials, we will use prede-
fined criteria based on those developed by Cochrane. Inadequate
concealment undermines the principle of randomisation, because
participants may then be allocated to a treatment according to
prognostic variables rather than by pure chance. Therefore, two
review authors will independently assess risk of bias for each study
using the criteria outlined in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We will resolve any
disagreements by discussion or by involving another author. We
will assess the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
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6. Selective outcome reporting.
We will judge each potential source of bias as high, low or unclear
and provide a supporting quotation from the study report together
with a justification for our judgment in the ’Risk of bias’ table.
We will summarise the ’Risk of bias’ judgements across different
studies for each of the domains listed. We will consider blinding
separately for different key outcomes where necessary (e.g. for
unblinded outcome assessment, risk of bias for all-cause mortality
may be very different than for a patient-reported anxiety scale).
Where information on risk of bias relates to unpublished data or
correspondence with a trialist, we will note this in the ’Risk of bias’
table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Where inadequate details of randomisation and other characteris-
tics of trials are provided, we will contact the authors of the studies
in order to obtain further information. Non-concurrence in qual-
ity assessment will also be reported.
Measures of treatment effect
Dichotomous data
For binary outcomes we will calculate a standard estimation of
the random-effects model risk ratio (RR) and its 95% confidence
interval (CI). It has been shown that a random-effects model has a
good generalisability (Furukawa 2002) and that RR is more intu-
itive (Boissel 1999) than odds ratio. Furthermore, odds ratios tend
to be interpreted as RR by clinicians (Deeks 2000). This may lead
to anoverestimationof the impressionof the effect (Higgins 2011).
For all primary outcomes we will calculate the number needed to
treat for an additional beneficial or harmful outcome (NNTB or
NNTH) and its 95% CI using Visual Rx (www.nntonline.net/),
taking account of the event rate in the control group.
Continuous data
(1) Summary statistics
It is likely that different studies have used varied panic rating scales;
therefore we will use standardised mean difference (SMD). If all
included studies have used the same instrument, we will use mean
difference (MD).
(2) Endpoint versus change data
Trials usually report results either using endpoint means and stan-
dard deviation (SD) of scales or using change in mean values from
baseline of assessment rating scales. We prefer to use scale end-
point data, which typically cannot have negative values and are
easier to interpret from a clinical point of view. If endpoint data
are unavailable, we will use the change data in separate analyses.
In case we use MD, we will pool results based on change data and
endpoint data in the same analysis.
Considering that clinical trials for panic disorder are usually small
and that data distribution is difficult to assess for studies with
small samples, in this review priority will be given to the use and
analysis of dichotomous variables both for efficacy and acceptabil-
ity. Where outcome data or SDs are not recorded, authors will be
asked to supply the data. When only the standard error (SE) or t-
statistics or P values are reported, SDs will be calculated accord-
ing to Altman (Altman 1996). In the absence of data from the
authors, the mean value of known SDs will be calculated from the
group of included studies according to Furukawa and colleagues
(Furukawa 2006).We will check that the original SDs are properly
distributed, so that the imputed SD represents the average.
Relative treatment rankings
We will estimate the ranking probabilities for all treatments of be-
ing at each possible rank.Wewill also obtain a treatment hierarchy
using the surface under the cumulative ranking curve (SUCRA)
and mean ranks (Salanti 2011). SUCRA can also be re-expressed
as a percentage interpreted as the percentage of effectiveness/ac-
ceptability of an intervention that would be ranked first without
uncertainty.
Unit of analysis issues
Cluster-randomised trials
In cluster-randomised trials groups of individuals rather than in-
dividuals are randomised to different interventions. If we iden-
tify cluster placebo-controlled randomised trials, we will use the
generic inverse variance technique, if such trials have been appro-
priately analysed taking into account intraclass correlation coeffi-
cients to adjust for cluster effects.Where trialists have not adjusted
for the effects of clustering, we will attempt to do this by obtaining
an intracluster correlation coefficient and then following the guid-
ance given in chapter 16.3.4 of the Cochrane Handbook (Higgins
2011).
Cross-over trials
Crossover trials are trials in which all participants receive both the
control and intervention treatment but in a different order. The
major problem is a carry-over effect from the first phase to the
second phase of the study, especially if the condition of interest is
unstable (Elbourne 2002). As this is the case with panic disorder,
randomised cross-over studies will be included but only data up
to the point of first cross-over will be used.
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Studies with multiple treatment groups
For the standard, pair-wise meta-analysis, if the arms involve one
placebo arm and two or more arms of different classes of antide-
pressants, we will compare each arm with placebo separately. In
this case, a possibility of unit of analysis error can occur, resulting
in double counting. In order to avoid that, we will include each
pair-wise comparison separately, according to the recommenda-
tions in the Cochrane Handbook for Systematic Reviews of Interven-
tions, section 16.5.4 (Higgins 2011). If the variable is dichoto-
mous, we will divide the shared intervention group evenly among
the comparisons. If the variable is continuous, only the total num-
ber of participants will be divided up, and the means and SDs will
be left unchanged.
For the network meta-analysis, multi-arm studies where the same
medication at different doses is compared will remain intact with
no adjustments to the numerator or denominator of the shared in-
tervention group. We will account for the correlation between the
effect sizes from multi-arm studies using the approach suggested
in Higgins 1996 and Dias 2013.
Dose-ranging studies
Dose-ranging studies, i.e. where different doses of the same med-
ication are compared to each other, will also be included and the
different dose arms will be pooled and considered to be one so
long as they are within the standard range (see above).
Dealing with missing data
We will try to contact the study authors for all relevant missing
data.
(1) Dichotomous outcomes
Response, or remissionon treatment, will be calculated using an in-
tention-to-treat analysis (ITT). We will follow the principle ’once
randomised always analysed’. Where participants left the study
before the intended endpoint, it will be assumed that they would
have experienced the negative outcome. The validity of the above
assumption will be tested by sensitivity analysis, applying worst
and best case scenarios. When dichotomous outcomes are not re-
ported but the baseline mean and SD on a panic disorder scale
are reported, we will calculate the number of responding or re-
mitted participants according to a validated imputation method
(Furukawa 2005). The validity of the above approach will be anal-
ysed by sensitivity analysis. If necessary, authors of studies will be
contacted to obtain data and/or clarification.
(2) Continuous outcomes
Concerning continuous data, the Cochrane Handbook recom-
mends avoiding imputation of continuous data and suggests using
the data as presented by the original authors. Where ITT data are
available they will be preferred to ’per-protocol analysis’. If nec-
essary, authors of studies will be contacted to obtain data and/or
clarification.
(3) Skewed or qualitative data
Skewed and qualitative data will be presented descriptively.
Several strategies will be considered for skewed data. If papers re-
port a mean and SD and there is also an absolute minimum pos-
sible value for the outcome, we will divide the mean by the SD.
If this is less than two then we will conclude that there is some
indication of skewness. If it is less than one (that is the SD is
bigger than the mean) then there is almost certainly skewness. If
papers have not reported the skewness and simply report means,
SDs and sample sizes, these numbers will be used. Because there is
a possibility that these data may not have been properly analysed,
and can also be misleading, analyses will be conducted with and
without these studies. If the data have been log-transformed for
analysis, and the geometric means are reported, skewness will be
reduced. This is the recommended method of analysis of skewed
data (Higgins 2011). If papers use non-parametric tests and de-
scribe averages using medians, they cannot be formally pooled
in the analysis. We will follow the recommendation made in the
Cochrane Handbook that results of these studies be reported in a
table in our review, along with all other papers. This means that
the data will not be lost from the review and the results can be
considered when drawing conclusions, even if they cannot be for-
mally pooled in the analyses.
(4) Missing statistics
When only P or SE values are reported, we will calculate SDs
(Altman 1996). In the absence of supplementary data after re-
quests to the authors, the SDs will be calculated according to a
validated imputation method (Furukawa 2006). We will examine
the validity of these imputations in the sensitivity analyses.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are de-
scribed in section 10 of the Cochrane Handbook (Higgins 2011).
A funnel plot is usually used to investigate publication bias. How-
ever, it has a limited role when there are only few studies of similar
size. Secondly, asymmetry of a funnel plot does not always reflect
publication bias. Visual inspection of funnel plots will be used
to assess publication bias as well as the statistical test for funnel
plot asymmetry proposed by Eggers or Rücker (Higgins 2011).
We will not use funnel plots for outcomes if there are 10 or fewer
studies, or if all studies are of similar size. We will examine small
study effects, including publication bias, in the network through
network meta-regression (Chaimani 2012).
Assessment of transitivity across treatment
comparisons
Transitivity characterises a network of interventions when the dis-
tributions of potential effect modifiers (as described above) are
balanced across all pair-wise comparisons. Transitivity can be in-
8Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
terpreted as the extension of the clinical and methodological het-
erogeneity across the network of different comparisons, and is nec-
essary to ensure a valid network meta-analysis. We will evaluate
transitivity in this review as follows.
(1) We will assess whether the included interventions are similar
when they are evaluated in RCTs with different designs; for exam-
ple, whether antidepressants are administered in the same way in
studies comparing antidepressants to placebo and in those com-
paring antidepressants to benzodiazepines.
(2) We will compare the distribution of the potential effect mod-
ifiers across the different pair-wise comparisons.
Data synthesis
Methods for direct comparisons (pair-wise meta-analysis)
Random-effects pair-wise meta-analyses will be conducted for ev-
ery treatment comparison with at least two studies, using Stata
2013 (StataCorp 2013). A random-effects model is considered
preferable here since it allows for variation across studies evenwhen
there is no evidence of statistical heterogeneity. It gives amore con-
servative estimate than the fixed-effect model. We note that the
random-effects model gives added weight to small studies, which
can either increase or decrease the effect size. We will also apply
a fixed-effect model, on primary outcomes only, to see whether it
markedly changes the effect size.
Methods for network meta-analysis (NMA)
A random-effects NMA, taking into account the correlations in-
duced by multi-arm trials, will be conducted in a Bayesian frame-
work and implemented using WinBUGS 1.4.3 (Winbugs 2012).
There are three possible models that could be fitted.
1. A class (lumped) model.
2. An individual treatment (possibly dose-specific) model.
3. A hierarchical model where we include both class and
treatments.
We will investigate models depending on the available data. The
goodness of fit of the model to the data will be measured by the
posterior mean of the residual deviance. This is defined as the dif-
ference between the deviance for the fitted model and the deviance
for the saturated model, where deviance measures the fit of the
model to the data points using the likelihood function. Where
necessary we will examine leverage plots to help identify any spe-
cific data points (trial arms) that were fitting poorly in eachmodel.
A leverage plot displays the leverage (a measure of influence equal
to the contribution of each trial arm to PD, the effective number
of parameters) versus the signed, square root of the residual de-
viance (a measure of fit) for each data point. Points with a high
leverage are influential, which means that they have a strong in-
fluence on the model parameters that generate their fitted values.
Convergence will be assessed using two chains and based on the
Brooks-Gelman-Rubin diagnostic tool in WinBUGS.
Assessment of statistical heterogeneity
In the standard pair-wise meta-analyses we will allow separate het-
erogeneity variances to be estimated for each pair-wise comparison
(as is the standard approach in Cochrane systematic reviews). In
the NMA we will assume an homogeneous between-study vari-
ability across studies (Lu 2004).
For the pair-wise meta-analyses we will statistically assess hetero-
geneity using the I2 statistic, using the following thresholds to aid
interpretation (section 9.5.2, Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity.
We will also use the Chi2 test and its P value to determine the
direction and magnitude of the treatment effects. A P value of
0.10 will be used as a threshold of statistical significance, since the
Chi2 test may be underpowered to detect statistical heterogeneity
should it exist.
For the NMA the statistical assessment of heterogeneity in the en-
tire network will be based on the magnitude of the heterogeneity
variance parameter, Tau2 estimated from the model. For dichoto-
mous outcomes the magnitude of the heterogeneity variance will
be compared with the empirical distribution derived by Turner
(Turner 2012). Empirical distributions for Tau2 have been devel-
oped recently also for continuous data (Rhodes 2015).
Inconsistency can be considered an additional layer of heterogene-
ity which can occur in networks of evidence. It can occur when
there is a discrepancy between a direct and indirect estimate of
treatment effect. As a first step, we will investigate the presence of
inconsistency locally, using a ’loop-specific’ approach. A loop of
evidence is formed by at least three treatments which have been
compared in studies forming a closed path in the network (e.g. the
triangle A-B-C). We will calculate the difference between indirect
and direct estimates in each closed loop and apply a loop-specific
z-test. We will report the percentage of inconsistent loops in the
network. The loop-specific approach cannot infer about inconsis-
tency across the whole network. We will also use global goodness-
of-fit statistics to compare a model assuming consistency with a
model that does not. In case of considerable inconsistency we will
investigate possible sources of it (e.g. mistakes in data extraction
or in data entry).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses are often exploratory in nature and should be
interpreted cautiously: firstly, because they often involve multiple
analyses leading to false positive results; and secondly, because these
analyses lack power and are more likely to result in false negative
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results. Therefore, wewill perform the following subgroup analysis
on the primary outcomes only.
• People suffering from panic disorder without agoraphobia
versus people suffering from panic disorder with agoraphobia.
Sensitivity analysis
The following sensitivity analyses have been planned a priori. We
will examine if the results change and check for the robustness of
the observed findings by:
1. excluding trials with imputed response rate; and
2. studies using as hoc outcome scale versus studies using a
validated scale (for responses and remission outcomes only).
Our routine comparisons of random-effects and fixed-effect mod-
els, as well as our secondary outcomes of remission rates and con-
tinuous severity measures, may be considered additional forms of
sensitivity analyses.
’Summary of findings’ table
There is no currently agreed format for ’Summary of findings’
tables from NMAs. However, in case a format for such a table
becomes available during the preparation of this review, we may
decide to use it and we will summarise the findings, applying the
GRADE approach (Higgins 2011).
A C K N OW L E D G E M E N T S
Disclaimer
The views and opinions expressed herein are those of the authors
and do not necessarily reflect those of the National Institute for
Health Research (NIHR), National Health Service (NHS) or the
Department of Health.
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A P P E N D I C E S
Appendix 1. CCDANCTR-References Register search
CCDANCTR-Refs Search 1 (panic):
#1. panic or agoraphobi*
#2. (antidepress* or anti-depress* or “anti depress*” or MAOI* or RIMA* or “monoamine oxidase inhibit*” or ((serotonin or nore-
pinephrine or noradrenaline or neurotransmitter* or dopamin*) NEAR (uptake or reuptake or re-uptake or “re uptake”)) or SSRI* or
SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or pharmacotherap* or psychotropic* or “drug therapy”)
#3. (agomelatine or alaproclate or amoxapine or amineptine or amitriptylin* or amitriptylinoxide or atomoxetine or befloxatone
or benactyzine or binospirone or brofaromine or (buproprion or amfebutamone) or butriptyline or caroxazone or cianopramine or
cilobamine or cimoxatone or citalopram or (chlorimipramin* or clomipramin* or chlomipramin* or clomipramine) or clorgyline
or clovoxamine or (cx157 or tyrima) or demexiptiline or deprenyl or (desipramine* or pertofrane) or desvenlafaxine or dibenzepin
or diclofensine or dimetacrin* or dosulepin or dothiepin or doxepin or duloxetine or desvenlafaxine or dvs-233 or escitalopram or
etoperidone or femoxetine or fluotracen or fluoxetine or fluvoxamine or (hyperforin or hypericum or “st john*”) or imipramin* or
iprindole or iproniazid* or ipsapirone or isocarboxazid* or levomilnacipran or lofepramine* or (“lu aa21004” or vortioxetine) or “lu
aa24530” or (ly2216684 or edivoxetine) or maprotiline or melitracen or metapramine or mianserin or milnacipran or minaprine
or mirtazapine or moclobemide or nefazodone or nialamide or nitroxazepine or nomifensine or norfenfluramine or nortriptylin* or
noxiptilin* or opipramol or oxaflozane or paroxetine or phenelzine or pheniprazine or pipofezine or pirlindole or pivagabine or pizotyline
or propizepine or protriptylin* or quinupramine or reboxetine or rolipram or scopolamine or selegiline or sertraline or setiptiline or
teciptiline or thozalinone or tianeptin* or toloxatone or tranylcypromin* or trazodone or trimipramine or venlafaxine or viloxazine or
vilazodone or viqualine or zalospirone)
#4. (benzodiazepin* or BZD or abecarnil or adinazolam or alprazolam or arfendazam or bentazepam or bretazenil or bromazepam or
brotizolam or camazepam or chlordiazepoxide or chlordesmethyldiazepam or cinolazepam or clobazam or clonazepam or clorazepate or
chlorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or desoxydemoxepam or devazepide or
diazepam or doxefazepam or estazolam or “ethyl loflazepate” or “cm 6912” or cm-6912 or etizolam or fludiazepam or flunitrazepam or
flurazepam or dealkylflurazepam or flutoprazepam or fosazepam or gidazepam or girisopam or halazepam or haloxazolam or ketazolam
or loflazepate or loprazolam or lorazepam or lormetazepam or meclonazepam or medazepam or metaclazepam or mexazolam or
midazolam or nerisopam or nimetazepam or nitrazepam or norchlordiazepoxide or norclobazam or nordazepam or norfludiazepam
or norflunitrazepam or oxazepam or “wy 3498” or wy-3498 or oxazolam or phenazepam or pinazepam or prazepam or premazepam
or propazepam or quazepam or ripazepam or serazepine or sograzepide or talampanel or tarazepide or temazepam or tetrazepam or
tofisopam or triazolam or (zolazepam or zaleplon or zolpidem or zopiclone or eszopiclone or z-drugs or “z drugs”) or *pam or *lam)
#5. (azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or
tandospirone or zalospirone or *piron*)
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#6. (#1 and (#2 or #3 or #4 or #5))
CCDANCTR-Refs Search 2 (ADNOS) :
#7. ((anxiety or anxious or ADNOS) and not (agoraphobi* or panic or (social NEAR (anxi* or phobi*)) or generalised or generalized
or obsessive or compulsive or OCD or PTSD or post-trauma* or “post trauma*” or posttrauma*))
#8. (#7 and (#2 or #3 or #4 or #5))
Appendix 2. Other database searches
Biomedical database update searches will be restricted from 2014 to present.
Ovid MEDLINE databases
Epub Ahead of Print, In-Process &OtherNon-Indexed Citations, OvidMEDLINE(R) Daily andOvidMEDLINE(R) 1946 to Present
1 (panic or agoraphobi*).mp.
2 exp Antidepressive Agents/
3 exp Neurotransmitter Uptake Inhibitors/
4 exp Monoamine Oxidase Inhibitors/
5 (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline or
nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or
antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp.
6 (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone or
Benactyzine or Binospirone or Brofaromine or (Buproprion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or
Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline
or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin
or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram
or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or St John*) or Imipramin*
or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or (Lu AA21004 or Vortioxetine) or
Lu AA24530 or (LY2216684 or Edivoxetine) or Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine
or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptylin*
or Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or
Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or
Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramine or Venlafaxine
or Viloxazine or Vilazodone or Viqualine or Zalospirone).mp.
7 exp Benzodiazepines/
8 (benzodiazepin* or BZD or abecarnil or adinazolam or alprazolam or arfendazam or bentazepam or bretazenil or bromazepam or
brotizolam or camazepam or chlordiazepoxide or chlordesmethyldiazepam or cinolazepam or clobazam or clonazepam or clorazepate or
chlorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or desoxydemoxepam or devazepide
or diazepam or doxefazepam or estazolam or ethyl loflazepate or cm 6912 or cm-6912 or etizolam or fludiazepam or flunitrazepam or
flurazepam or dealkylflurazepam or flutoprazepam or fosazepam or gidazepam or girisopam or halazepam or haloxazolam or ketazolam
or loflazepate or loprazolam or lorazepam or lormetazepam or meclonazepam or medazepam or metaclazepam or mexazolam or
midazolam or nerisopam or nimetazepam or nitrazepam or norchlordiazepoxide or norclobazam or nordazepam or norfludiazepam
or norflunitrazepam or oxazepam or wy 3498 or wy-3498 or oxazolam or phenazepam or pinazepam or prazepam or premazepam
or propazepam or quazepam or ripazepam or serazepine or sograzepide or talampanel or tarazepide or temazepam or tetrazepam or
tofisopam or triazolam or zolazepam or zaleplon or zolpidem or zopiclone or eszopiclone or z-drugs or z drugs).mp.
9 (azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or
tandospirone or zalospirone).mp.
10 (placebo* or dummy or sugar pill).mp.
11 or/2-10
12 randomized controlled trial.pt.
13 randomi#ed.ti,ab,kf.
14 controlled clinical trial.pt.
15 Double-Blind Method/
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16 clinical trials as topic.sh.
17 randomly.ab.
18 (RCT or at random or (random* adj (assign* or allocat* or divid* or division or number))).ti,ab,kf.
19 trial.ti,kf.
20 (animals not (humans and animals)).sh.
21 or/12-19
22 21 not 20
23 1 and 11 and 22
24 (NLM or HSR).ro.
25 23 and 24
26 (2014* or 2015* or 2016*).yr,ed.
27 25 and 26
28 remove duplicates from 27
Cochrane Central Register of Controlled Trials (CENTRAL)
Current Issue
#1MeSH descriptor: [Panic] this term only
#2MeSH descriptor: [Panic Disorder] this term only
#3MeSH descriptor: [Agoraphobia] this term only
#4(panic or agoraphobi*)
#5#1 or #2 or #3 or #4
#6MeSH descriptor: [Antidepressive Agents] explode all trees
#7MeSH descriptor: [Neurotransmitter Uptake Inhibitors] explode all trees
#8MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees
#9(antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline or
nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or
antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic* or psychotropic*)
#10(Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone
or Benactyzine or Binospirone or Brofaromine or (Buproprion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or
Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline
or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin
or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram
or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or St John*) or Imipramin*
or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or (Lu AA21004 or Vortioxetine) or
Lu AA24530 or (LY2216684 or Edivoxetine) or Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine
or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptylin*
or Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or
Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or
Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramine or Venlafaxine
or Viloxazine or Vilazodone or Viqualine or Zalospirone)
#11MeSH descriptor: [Benzodiazepines] explode all trees
#12(benzodiazepin* or BZD or abecarnil or adinazolam or alprazolam or arfendazam or bentazepam or bretazenil or bromazepam or
brotizolam or camazepam or chlordiazepoxide or chlordesmethyldiazepam or cinolazepam or clobazam or clonazepam or clorazepate or
chlorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or desoxydemoxepam or devazepide
or diazepam or doxefazepam or estazolam or ethyl loflazepate or cm 6912 or cm-6912 or etizolam or fludiazepam or flunitrazepam or
flurazepam or dealkylflurazepam or flutoprazepam or fosazepam or gidazepam or girisopam or halazepam or haloxazolam or ketazolam
or loflazepate or loprazolam or lorazepam or lormetazepam or meclonazepam or medazepam or metaclazepam or mexazolam or
midazolam or nerisopam or nimetazepam or nitrazepam or norchlordiazepoxide or norclobazam or nordazepam or norfludiazepam
or norflunitrazepam or oxazepam or wy 3498 or wy-3498 or oxazolam or phenazepam or pinazepam or prazepam or premazepam
or propazepam or quazepam or ripazepam or serazepine or sograzepide or talampanel or tarazepide or temazepam or tetrazepam or
tofisopam or triazolam or zolazepam or zaleplon or zolpidem or zopiclone or eszopiclone or z-drugs or z drugs)
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#13(azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or
tandospirone or zalospirone)
#14(placebo* or dummy or “sugar pill*”)
#15#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16#5 and #15
#17(2014* or 2015* or 2016* or 2017*)
#18#16 and #17
Ovid Embase
1980 to present
1 Panic/
2 Agoraphobia/
3 (panic or agoraphobi*).mp.
4 or/1-3
5 exp antidepressant agent/
6 exp serotonin uptake inhibitor/
7 exp serotonin noradrenalin reuptake inhibitor/
8 exp noradrenalin uptake inhibitor/
9 (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone or
Benactyzine or Binospirone or Brofaromine or (Buproprion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or
Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline
or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin
or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram
or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or St John*) or Imipramin*
or Iprindole or Iproniazid* or Ipsapirone or
Isocarboxazid* or Levomilnacipran or Lofepramine* or (LuAA21004 orVortioxetine) or LuAA24530 or (LY2216684 orEdivoxetine) or
Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone
or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozane or
Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or
Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or
Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramine or Venlafaxine or Viloxazine or Vilazodone or Viqualine
or Zalospirone).mp.
10 (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline or
nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or
antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp.
11 exp Benzodiazepine derivative/
12 (benzodiazepin* or BZD or abecarnil or adinazolam or alprazolam or arfendazam or bentazepam or bretazenil or bromazepam or
brotizolam or camazepam or chlordiazepoxide or chlordesmethyldiazepam or cinolazepam or clobazam or clonazepam or clorazepate or
chlorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or desoxydemoxepam or devazepide
or diazepam or doxefazepam or estazolam or ethyl loflazepate or cm 6912 or cm-6912 or etizolam or fludiazepam or flunitrazepam or
flurazepam or dealkylflurazepam or flutoprazepam or fosazepam or gidazepam or girisopam or halazepam or haloxazolam or ketazolam
or loflazepate or loprazolam or lorazepam or lormetazepam or meclonazepam or medazepam or metaclazepam or mexazolam or
midazolam or nerisopam or nimetazepam or nitrazepam or norchlordiazepoxide or norclobazam or nordazepam or norfludiazepam
or norflunitrazepam or oxazepam or wy 3498 or wy-3498 or oxazolam or phenazepam or pinazepam or prazepam or premazepam
or propazepam or quazepam or ripazepam or serazepine or sograzepide or talampanel or tarazepide or temazepam or tetrazepam or
tofisopam or triazolam or zolazepam or zaleplon or zolpidem or zopiclone or eszopiclone or z-drugs or z drugs).mp.
13 (azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or
tandospirone or zalospirone).mp.
14 (placebo* or dummy or sugar pill*).mp.
15 or/5-14
16 major clinical study/
17 Randomized controlled trial/
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18 Controlled clinical study/
19 double blind procedure/
20 randomization/
21 (RCT or randomi#ed).ti,ab,kw.
22 ((at random or random*) adj2 (allocat* or assign* or divide* or division or number)).ti,ab,kw.
23 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab,kw.
24 or/16-23
25 ((animal or nonhuman) not (human and (animal or nonhuman))).de.
26 24 not 25
27 4 and 15 and 26
28 elsevier.cr.
29 27 and 28
30 (random* adj sampl* adj7 (“cross section*” or questionnaire*1 or survey* or database*1)).ti,ab. not (comparative
study/ or controlled study/ or randomi?ed controlled.ti,ab. or randomly assigned.ti,ab.)
31 Cross-sectional study/ not (randomized controlled trial/ or controlled clinical study/ or controlled study/ or
randomi?ed controlled.ti,ab. or control group$1.ti,ab.
32 (((case adj control$) and random$) not randomi?ed controlled).ti,ab.
33 (Systematic review not (trial or study)).ti.
34 (review.ab. and review.pt.) not trial.ti.
35 or/30-34
36 29 not 35
37 (2014* or 2015* or 2016*).yr,dd.
38 36 and 37
Ovid PsycINFO
1987 to present
1 Panic Attack/ or Panic/ or Panic Disorder/
2 Agoraphobia/
3 (panic or agoraphobi*).mp.
4 adnos.ti,ab,id.
5 (anxiety disorder* adj2 otherwise specified).ti,ab,id.
6 or/1-5
7 exp Antidepressant Drugs/
8 Neurotransmitter Uptake Inhibitors/ or exp serotonin norepinephrine reuptake inhibitors/ or exp serotonin reuptake inhibitors/
9 exp Monoamine Oxidase Inhibitors/
10 exp Tricyclic Antidepressant Drugs/
11 (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline or
nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or
antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp.
12 (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone
or Benactyzine or Binospirone or Brofaromine or (Buproprion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or
Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline
or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin
or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram
or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or St John*) or Imipramin*
or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or (Lu AA21004 or Vortioxetine) or
Lu AA24530 or (LY2216684 or Edivoxetine) or Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine
or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptylin*
or Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or
Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or
Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramine or Venlafaxine
or Viloxazine or Vilazodone or Viqualine or Zalospirone).mp.
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13 exp benzodiazepines/
14 (benzodiazepin* or BZD or abecarnil or adinazolam or alprazolam or arfendazam or bentazepam or bretazenil or bromazepam or
brotizolam or camazepam or chlordiazepoxide or chlordesmethyldiazepam or cinolazepam or clobazam or clonazepam or clorazepate or
chlorazepate or clotiazepam or cloxazolam or delorazepam or demoxepam or desmethyldiazepam or desoxydemoxepam or devazepide
or diazepam or doxefazepam or estazolam or ethyl loflazepate or cm 6912 or cm-6912 or etizolam or fludiazepam or flunitrazepam or
flurazepam or dealkylflurazepam or flutoprazepam or fosazepam or gidazepam or girisopam or halazepam or haloxazolam or ketazolam
or loflazepate or loprazolam or lorazepam or lormetazepam or meclonazepam or medazepam or metaclazepam or mexazolam or
midazolam or nerisopam or nimetazepam or nitrazepam or norchlordiazepoxide or norclobazam or nordazepam or norfludiazepam
or norflunitrazepam or oxazepam or wy 3498 or wy-3498 or oxazolam or phenazepam or pinazepam or prazepam or premazepam
or propazepam or quazepam or ripazepam or serazepine or sograzepide or talampanel or tarazepide or temazepam or tetrazepam or
tofisopam or triazolam or zolazepam or zaleplon or zolpidem or zopiclone or eszopiclone or z-drugs or z drugs).mp.
15 (azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or
tandospirone or zalospirone).mp.
16 (placebo* or dummy or sugar pill*).mp.
17 or/7-16
18 (RCT or at random or (random* adj (assign* or allocat* or divid* or division or number))).ti,ab,id.
19 trial.ti,id.
20 randomi#ed.ti,ab,id.
21 ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask* or dummy)).ti,ab,id.
22 (placebo* or dummy or sugar pill*).mp.
23 or/18-22
24 6 and 17 and 23
25 (2014* or 2015* or 2016*).yr,an.
26 24 and 25
27 ((anxiety or ADNOS) not (agoraphobi* or panic or (social adj3 (anxi* or phobi*)) or generalised or generalized or obsessive or
compulsive or OCD or PTSD or post-trauma* or post trauma* or posttrauma*)).ti,id,hw.
28 17 and 23 and 27
29 25 and 28
30 26 or 29
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